Impact of blood sampling on the circulating matrix metalloproteinases 1, 2, 3, 7, 8, and 9.
Author(s): Jung K, Klotzek S, Stephan C, Mannello F, Lein M
Publication: Clin Chem, 2008, Vol. 54, Page 772-3
PubMed ID: 18375496 PubMed Review Paper? No
Purpose of Paper
Conclusion of Paper
Studies
-
Study Purpose
The purpose of this study was to determine if blood matrix metalloproteinase (MMP) levels differ as a result of anticoagulant type or the presence of a coagulant accelerator.
Summary of Findings:
In general, MMP concentrations were higher in serum than in plasma specimens. In comparison to additive-free serum, serum treated with a coagulant accelerator (kaolin-coated granules) displayed significantly higher MMP-1, -8, and -9 levels. Conversely, levels of MMP-2, -3, and -7 were comparable among serum with and without additives as well as sodium citrate or lithium heparin treated plasma specimens.
Biospecimens
Preservative Types
- Frozen
Diagnoses:
- Normal
Platform:
Analyte Technology Platform Protein Automated electrophoresis/Bioanalyzer Pre-analytical Factors:
Classification Pre-analytical Factor Value(s) Biospecimen Aliquots and Components Blood and blood products Plasma
Serum
Biospecimen Acquisition Anticoagulant Potassium EDTA
Lithium heparin
Sodium citrate
None